Status:
UNKNOWN
Correlation Between PIF Maternal Serum Levels and Pregnancy Outcome
Lead Sponsor:
BioIncept LLC
Collaborating Sponsors:
Merck KGaA, Darmstadt, Germany
Conditions:
Pregnancy
Eligibility:
FEMALE
18+ years
Brief Summary
PIF: biomarker of pregnancy, miscarriage, premature birth, preeclampsia, placenta accreta. Except for serum hCG, no pregnancy-complication markers are widely employed to predict the need for medical ...
Detailed Description
We will assess PIF prospectively in maternal serum throughout viable pregnancy in order to assess its performance characteristics in predicting viability. More than 250 pregnancies after IVF will be s...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Women attending a perinatal center who are properly informed and willing to participate in this study. Women included in the participating center with previous pregnancy complication and pregnant women after IVF (SET or MET). PIF levels evaluation in maternal serum (P1 to 5) will be evaluated for all pregnant women.
- Exclusion criteria:
- Women who will refuse to participate in the program.
Exclusion
Key Trial Info
Start Date :
September 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT01805102
Start Date
September 1 2012
Last Update
March 6 2013
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale Women and Children's Center for Blood Disorders & Yale Fertility Center
New Haven, Connecticut, United States, 06511
2
Poissy St Germain Hospital
Poissy, Cedex, France, 78303
3
Lab Clement - Seine St Denis Hospital, Le Blanc Mesnil
Paris, France, 93150
4
Versailles St Quentin University
Poissy, France, 2493